News

Deal Announcements

DNAtriX Secures Series B Venture Capital

Thursday, October 16, 2014 5:45:00 AM PDT | VentureDeal
   Houston, Texas  --  Biotechnology company DNAtriX has raised $20 million in its second round of institutional venture capital financing.

DNAtriX is developing an oncolytic virus platform for the treatment of malignant glioma.

Morningside led the round, which included other previous investors Mercury Fund, Targeted Technology Fund and others.

The company said it would use the funding proceeds to advance its lead oncolytic virus product, DNX-2401.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1